Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy

Journal of the American Society of Nephrology

Volumn 25, Issue 6, 2014, Pages 1357-1366

  Hoxha, Elion ^a   Thiele, Ina ^a   Zahner, Gunther ^a   Panzer, Ulf ^a   Harendza, Sigrid ^a   Stahl, Rolf A K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AUTOANTIBODY; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR AUTOANTIBODY; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG; PLA2R1 PROTEIN, HUMAN; SERUM ALBUMIN;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MIDDLE AGED; MULTICENTER STUDY; PRIORITY JOURNAL; PROTEINURIA; REMISSION; TREATMENT OUTCOME; AGED; EPIDEMIOLOGY; FOLLOW UP; IMMUNOLOGY; META ANALYSIS; METABOLISM; NEPHROTIC SYNDROME; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AUTOANTIBODIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PROGNOSIS; PROSPECTIVE STUDIES; PROTEINURIA; RECEPTORS, PHOSPHOLIPASE A2; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 84906088212     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013040430     Document Type: Article

References (19)

1. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361: 11-21, 2009
2. Schieppati A, Mosconi L, Perna A, Mecca G, Bertani T, Garattini S, Remuzzi G: Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 329: 85-89, 1993
3. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-FresnedoG,MartínC,Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-JuárezG, Barrio V, Sierra M, Castellanos I, EspinosaM, Rivera F, Oliet A, Fernández-Vega F, Praga M; Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21: 697-704, 2010
4. Cattran DC, Pei Y, Greenwood CM, Ponticelli C, Passerini P, Honkanen E: Validation of a predictive model of idiopathic membranous nephropathy: Its clinical and research implications. Kidney Int 51: 901-907, 1997
5. van den Brand JAJG, Hofstra JM, Wetzels JFM: Prognostic value of risk score and urinary markers in idiopathicmembranous nephropathy. Clin J AmSoc Nephrol 7: 1242-1248, 2012
6. Hoxha E, Harendza S, Zahner G, Panzer U, Steinmetz O, Fechner K, Helmchen U, Stahl RA: An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 26: 2526-2532, 2011
7. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R,Mathieson PW, Ronco P, Brenchley PE, Wetzels JF: Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1735-1743, 2012
8. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V,Wetzels JF, Hofstra JM, Hoxha E, Stahl RA, Lambeau G, StöckerW, SchlumbergerW: Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 421: 213-218, 2013
9. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG,Malik FA, Erickson SB, Cosio FG, Cattran DC, Salant DJ: Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response inmembranous nephropathy. J Am Soc Nephrol 22: 1543-1550, 2011
10. Stahl R, Hoxha E, Fechner K: PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 363: 496-498, 2010
11. Pruchno CJ, Burns MM, Schulze M, Johnson RJ, Baker PJ, Alpers CE, Couser WG: Urinary excretion of the C5b-9 membrane attack complex of complement is a marker of immune disease activity in autologous immune complex nephritis. Am J Pathol 138: 203-211, 1991
12. Salant DJ, Darby C, Couser WG: Experimental membranous glomerulonephritis in rats.Quantitative studies of glomerular immune deposit formation in isolated glomeruli and whole animals. J Clin Invest 66: 71-81, 1980
13. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, NikamM, Poulton K,McWilliam L, Short CD, VenningM, Brenchley PE: Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 83: 940-948, 2013
14. Ponticelli C, Altieri P, Scolari F, Passerini P, Roccatello D, Cesana B, Melis P, Valzorio B, Sasdelli M, Pasquali S, Pozzi C, Piccoli G, Lupo A, Segagni S, Antonucci F, Dugo M, Minari M, Scalia A, Pedrini L, Pisano G, Grassi C, Farina M, Bellazzi R: A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy. J Am Soc Nephrol 9: 444-450, 1998
15. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF,Morrin PA, Lavoie S; Canadian Glomerulonephritis Study Group: A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Kidney Int 47: 1130-1135, 1995
16. Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A, Marasà M, Remuzzi G: Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1416-1425, 2012
17. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P: The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008
18. Appel GB: Rituximab in membranous nephropathy: Is it a first-line treatment? J Am Soc Nephrol 23: 1280-1282, 2012
19. Waldman M, Austin HA 3rd: Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1617-1630, 2012